{"id":18077,"date":"2022-10-27T14:14:33","date_gmt":"2022-10-27T14:14:33","guid":{"rendered":"https:\/\/clinlabint.com\/?p=18077"},"modified":"2022-10-27T14:14:33","modified_gmt":"2022-10-27T14:14:33","slug":"kupando-raises-e13-million-in-series-a-funding-round","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/kupando-raises-e13-million-in-series-a-funding-round\/","title":{"rendered":"Kupando raises \u20ac13 million in Series A funding round"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Kupando raises \u20ac13 million in Series A funding round<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Kupando, a Berlin-based biopharmaceutical company developing TLR 4\/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, has closed its Series A funding round which raised \u20ac13 million.<\/h3>\n

<\/p>\n

The funds will be used to complete IND-enabling work and to initiate the clinical development of Kupando\u2019s lead candidate KUP101 in a solid tumour indication. KUP101 is the only TLR 4\/7 agonist in development, and consists of two small molecules, a TLR 4 agonist and a TLR 7 agonist, co-encapsulated in a liposomal formulation. The compounds induce a broad immune response, which will facilitate their development as an anti-tumour agent, as a stand-alone product, in combination with other anti-tumour modalities, or a prophylactic vaccine for infectious diseases. The induction of cross-reactive anti-bodies and a broad cellular response are promising features for a broad portfolio of indications, in particular where different strains and antigens play a role, like influenza, HPV and others. A high target specificity in the absence of relevant off-targets are indicators for a promising safety profile.<\/p>\n

The investment was led by Remiges Ventures and co-led by LifeCare Partners with an additional investment by Brandenburg Kapital, High-Tech Gr\u00fcnderfonds, Ventura Biomed Investors and undisclosed family offices.<\/p>\n

Kazuhiko Nonomura, PhD Principal at Remiges Ventures, the lead investor said: \u201cWe are impressed by the tremendous progress made by Kupando since its inception. Kupando is a real pioneer in the development of a novel innate immunity stimulator, and we look forward to working with the team and supporting the advancement of KUP101 into clinical development.\u201d<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n